Practical points in the medical treatment of overactive bladder and nocturia in the elderly
- PMID: 28757708
- PMCID: PMC5509172
- DOI: 10.1016/j.tcmj.2015.12.003
Practical points in the medical treatment of overactive bladder and nocturia in the elderly
Abstract
The prevalence of overactive bladder (OAB) increases with age. Degeneration of the central nervous system in the elderly has been proposed as one of the pathogenic factors of OAB. Antimuscarinic therapy is effective in the treatment of OAB; however, intolerable systemic adverse events and cognitive dysfunction during treatment with nonselective antimuscarinic agents is of growing concern in elderly patients. The newly developed beta-3 adrenoceptor agonist mirabegron does not adversely affect flow rate and detrusor pressure, and its therapeutic efficacy and tolerability are similar in patients aged > 65 years and > 75 years, suggesting it might be the therapeutic choice in older patients with OAB. Nocturia can cause sleep deprivation at night and increase daytime sleepiness and loss of energy in the elderly. Desmopressin add-on therapy is effective in improving nocturia and storage symptoms. However, elderly patients with a baseline serum sodium level below the normal range are at high risk of developing significant hyponatremia.
Keywords: Aging; BPH; Lower urinary tract dysfunction; Nocturnal polyuria.
Conflict of interest statement
Conflict of interest: none.
Similar articles
-
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23. BJU Int. 2015. PMID: 25639296 Clinical Trial.
-
Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).Eur Urol Focus. 2020 Jul 15;6(4):729-737. doi: 10.1016/j.euf.2019.10.019. Epub 2019 Nov 11. Eur Urol Focus. 2020. PMID: 31718957 Clinical Trial.
-
Lower Urinary Tract Symptoms: What's New in Medical Treatment?Eur Urol Focus. 2018 Jan;4(1):17-24. doi: 10.1016/j.euf.2018.04.005. Epub 2018 Apr 14. Eur Urol Focus. 2018. PMID: 29665997 Review.
-
β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.Int Urol Nephrol. 2013 Feb;45(1):53-60. doi: 10.1007/s11255-012-0343-5. Epub 2012 Dec 2. Int Urol Nephrol. 2013. PMID: 23212147 Clinical Trial.
-
A drug safety evaluation of mirabegron in the management of overactive bladder.Expert Opin Drug Saf. 2016 May;15(5):689-96. doi: 10.1517/14740338.2016.1165663. Epub 2016 Apr 21. Expert Opin Drug Saf. 2016. PMID: 26980445 Review.
Cited by
-
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.Drugs Aging. 2021 Jul;38(7):593-602. doi: 10.1007/s40266-021-00863-5. Epub 2021 May 24. Drugs Aging. 2021. PMID: 34027602
References
-
- Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J, et al. International Urogynecological Association;International Continence Society; Joint IUGA/ICS Working Group on Complications Terminology. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. Neurourol Urodyn. 2011;308:2–12. - PubMed
-
- Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80:90–6. - PubMed
-
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschom S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14. discussion 1314—5. - PubMed
-
- Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: a longitudinal population-based survey in men aged 45—103 years. Eur Urol. 2010;58:149–56. - PubMed
-
- Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000;48:721–5. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources